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Abstract: This review article considers the rising demand for patient-reported outcome measures 
(PROMs) in modern ophthalmic research and clinical practice. We review what PROMs are, 
how they are developed and chosen for use, and how their quality can be critically appraised. 
We outline the progress made to develop PROMs in each clinical subspecialty. We highlight 
recent examples of the use of PROMs as secondary outcome measures in randomized controlled 
clinical trials and consider the impact they have had. With increasing interest in using PROMs as 
primary outcome measures, particularly where interventions have been found to be of equivalent 
efficacy by traditional outcome metrics, we highlight the importance of instrument precision 
in permitting smaller sample sizes to be recruited. Our review finds that while there has been 
considerable progress in PROM development, particularly in cataract, glaucoma, medical retina, 
and low vision, there is a paucity of useful tools for less common ophthalmic conditions. Devel-
opment and validation of item banks, administered using computer adaptive testing, has been 
proposed as a solution to overcome many of the traditional limitations of PROMs, but further 
work will be needed to examine their acceptability to patients, clinicians, and investigators.
Keywords: patient-reported outcome measures, Rasch analysis, eye disease, randomized 
controlled trials
Introduction
Recent years have seen greater awareness of the importance of the patient voice in 
ophthalmology.6 This paradigm shift influences our understanding of the impact of 
disease, and the efficacy of interventions, with implications for both clinical practice 
and clinical trials. There has been a move away from the sole use of traditional outcome 
metrics (eg, visual acuity, intraocular pressure [IOP]) toward inclusion of metrics that 
matter as much, or possibly more, to patients and providers (eg, symptoms, quality of 
life [QoL], convenience, and cost of treatment). Patient-reported outcome measures 
(PROMs) seek to comprehensively capture these important outcomes.
PROMs are increasingly used in clinical trials to assess the impact of treatment 
from the patient perspective. They offer particular value as the primary outcome mea-
sure where two interventions have been established to be equally efficacious in terms 
of a traditional outcome measure (eg, IOP lowering effect), but where differences 
are anticipated in terms of side effects, cost, and convenience. Multiple randomized 
controlled clinical trials (RCTs) have recently completed or are in progress using 
PROMs as the primary outcome measure.7–10 PROM data from trials may be used to 
inform pharmaceutical labeling claims, clinical guideline development, reimbursement 
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decisions, and health policy. In addition, PROMs have 
potential application in clinical governance and quality 
assurance, performance management of health care provid-
ers, and integration into routine clinical practice.11,12 The 
international consortium for health outcome measurement 
(ICHOM) has proposed standard outcome sets including 
PROMs for clinical assessment of cataract (using Catquest-
9SF) and age-related macular degeneration (AMD) (using 
the Impact of Vision Impairment, IVI) (http://www.ichom.
org/medical-conditions/). Reporting of ICHOM outcome sets 
for ophthalmic conditions was recently mapped to current 
reporting practices in eight large eye centers internationally.14 
This exercise revealed wide variation in current reporting 
practice, and no reporting of vision or eye disease-related 
PROMs by any hospital. Potential barriers to extend the use 
of PROMS in routine clinical care include logistical, social, 
legal, technical, and cultural factors.12
This review outlines what PROMs are, explores PROMs 
development, and probes the extent to which they have had 
meaningful impact on clinical and research practice in mod-
ern ophthalmology.
What are PROMs?
PROMs are sets of questions, or “items,” that capture informa-
tion on health from the patients’ perspective. Some PROMs 
provide rudimentary summary information, while others 
provide detailed measurement suited to statistical analysis. 
Measurement of PROMs began in the 1950s, and there has 
been rapid expansion in the past two decades in all fields of 
health care, including ophthalmology. A small survey in 1998 
reveled that very few UK ophthalmologists were familiar with 
QoL outcome measures.15 In 2001, Massof and Rubin reported 
that more than 12 PROMs had been developed since 1980.16 
Now there are more than 160 PROM instruments in ophthal-
mology and optometry.17 Many have been developed for use in 
glaucoma, cataract, and low vision, but there are no validated 
PROMs for a large number of eye diseases and interventions.
There are many generic instruments (eg, EQ-5D, Short 
Form [SF]-36, Health Utilities Index-3 [HUI-3]), vision-
related instruments (eg, IVI, National Eye Institute-Vision 
Function Questionnaire, NEI-VFQ-25), and ocular disease-
specific PROM instruments (eg, Catquest-9SF). The plethora 
of available instruments presents a challenge – how should 
one be selected for use in clinical practice or a clinical trial?
Selecting a PROM
There is no “gold standard” PROM. In order to select a 
PROM, investigators and clinicians must choose the latent 
trait that they want to measure, in consultation with patients 
and their carers. This might be the impact of disease, or treat-
ment, on symptoms, daily activities, emotional well-being, or 
side effects, measured at one time point or longitudinally. The 
choice of PROM will depend on the rationale for assessment. 
For example, if the data will be used to provide in-depth infor-
mation to clinicians and patients on the impact of disease, 
then a disease-specific measure may be most appropriate. 
However, if data will be used for health economic evaluation, 
then a health utility measure, which seeks to take account of 
preferences for different health states, such as the EQ-5D, will 
be required. Impact on QoL is a frequently desired outcome 
measure, particularly by health policy makers. However, the 
challenge with measuring QoL is that it is a multidimensional 
construct. The latent traits encompassed within vision and 
eye disease-related QoL are proposed to include visual 
symptoms, ocular surface symptoms, general symptoms, 
emotional well-being, activity limitation, mobility, conve-
nience, health concerns, social well-being, and economic 
well-being, but are not necessarily limited to these.17 Each 
trait, or domain of interest, requires due consideration and 
measurement. Having chosen the latent trait or traits to be 
measured, a PROM can be selected from the pool of avail-
able instruments, and piloted for use to establish validity for 
use in a new patient or population context, or a new PROM 
may need to be developed. To better understand the multiple 
factors that should be considered, the next section explores 
what the ideal PROM might look like.
What does the ideal PROM look 
like?
Multiple approaches to evaluate PROMs have been pro-
posed18–22 and have informed the US Food and Drug Adminis-
tration’s guidance.23 In brief, important considerations include 
1) content development; 2) the psychometric properties of the 
instrument (judged using either Classical Test Theory, or Item 
Response Theory approaches, including Rasch analysis – see 
Boxes 1 and 2 for more details); 3) responsiveness; and 4) 
administration burden and resource implications.
The ideal PROM contains a necessary and sufficient set of 
questions (content) to measure a single underlying construct 
such as ocular surface symptoms (unidimensionality), or, 
for a multidimensional construct like QoL, a series of sets 
of questions, each demonstrating unidimensionality and 
together targeting each important element of the multidi-
mensional construct. It has a logical order of evenly spaced 
response categories. It is reliably able to distinguish between 
patients with different abilities or degrees of severity for each 
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Box 1 Classical test theory and item response theory
Analysis of patient-reported outcome measures has been centered on two approaches, Classical Test Theory (CTT), and item Response Theory 
(iRT).2
In CTT, each item is assumed to have equal difficulty, and each response score is assumed to have equal weight (eg, a score of 4 for “extreme 
difficulty” is assumed to have twice the value of a score of 2 for “mild difficulty”). Summary scores are assumed to represent measurement of 
the underlying trait (eg, quality of life). In IRT, both items and responders are scaled according to responses, which are assumed to reflect the 
different ability of responders and the different difficulty of items. Ordering of category responses is explicitly tested to ensure that “extreme 
difficulty” scores more highly across responders than “mild difficulty.” Rasch analysis is a special case of IRT, where the data are fit to a simple 
measurement model. This creates valid measurement to which parametric statistics can be applied. Massof has discussed the theoretical constructs 
and methodology as applied to ophthalmology in detail.13
Box 2 The importance of Rasch analysis
The Rasch model provides interval-level scoring to enable examination of each unidimensional construct. Rasch analysis permits quantitative 
psychometric assessment of each latent trait and generates measurement data that are readily amenable to statistical analysis, whereas summary 
scoring does not. The classical test theory approach, which does not use Rasch analysis, is defined by the use of summary scoring (simple adding up 
of ordinal values assigned to response options) and a high-level reliance on simple reliability statistics like Cronbach’s alpha. The latter statistic is 
calculated from pairwise correlations between items and provides rudimentary insight into an instrument’s internal consistency. Gothwal et al have 
argued that Rasch scaling achieves smaller standard errors of the measures and further enhances precision by applying a logistic transformation 
to expand the range of measurement, thereby reducing ceiling and floor effects.1 An important implication of this for clinical trials is that Rasch-
validated instruments require a smaller sample size to detect significant differences in outcomes. 
Rasch analysis has therefore been used to “re-engineer” some of the popular existing instruments, such as the Visual Function Index-14 (VF-14) 
and Nei-vFQ-25. For example, the vF-14 was used before and after cataract surgery, and re-engineered into a shorter instrument, achieving both 
reduced respondent burden and administration time, and precision 2.5 times greater than the original instrument.1 Doubling the precision of the 
primary outcome measure halves the required sample size, with very important cost implications for clinical trials. Flaws in the psychometric 
properties of the, widely used, NEI-VFQ-25 have been identified by multiple investigators, and Rasch re-engineered instruments have been 
proposed.3–5
item, and between patients at each end of the range of the 
construct (measurement precision), with neither significant 
floor nor ceiling effects (targeting). The instrument score 
correlates with important clinical measures such as visual 
acuity (concurrent validity), and with any existing instru-
ments purporting to measure the same construct (convergent 
validity), while not correlating highly with instruments 
purporting to measure a different construct (discriminant 
validity). It can discriminate between clinically distinct 
groups and is responsive to detecting clinically important 
changes over time. The instrument demonstrates test–retest 
reliability when repeated. Specific quality scoring criteria 
have been outlined in detail by Prem Senthil et al.24 Further 
considerations include the cost of the instrument (some are 
not freely available), the availability of the PROM in different 
languages, the staffing administration requirements, and the 
patient response burden. One of the most frequent trade-offs 
that must be made is between selecting a short PROM that 
is readily applicable in a busy clinical or research context, 
and selecting a PROM that provides comprehensive insight, 
but takes much longer to administer. It is also important to 
note that a PROM developed for one target disease or patient 
population in one cultural context may have poor targeting 
of item difficulty to respondent ability in another disease or 
population, which is why validation is necessary.17
Generic PROMs
Generic, multi-attribute, health-related utility instruments 
have been used for over three decades, and the most widely 
used include the EQ-5D, SF-6D, and HUI. In these instru-
ments, answers to a series of questions yield raw health state 
scores that can be transformed into a utility value, where 1 
represents perfect health and 0 is death. Utility values are used 
to calculate quality-adjusted life years (QALY) lost or gained 
as a result of a disease state or health care intervention. The 
health state weights are obtained using cardinal preference 
measurement approaches, such as the time trade-off or the 
standard gamble.
The EQ-5D instrument was developed by the EuroQol 
Group almost 30 years ago.25 It has been translated into 
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over 100 official languages and is widely used. It includes 
five questions on mobility, self-care, usual activities, anxi-
ety/depression, and pain/discomfort. The original EQ-5D 
includes three levels (3L) for each question, resulting in 243 
possible health states. A five-level (5L) instrument has been 
introduced more recently, yielding 3,125 health states.26 A 
further three bolt-on items have been developed for EQ-5D, 
including a vision bolt on.27 The preference weights for the 
EQ-5D-3L were originally obtained from a UK population 
sample using time-trade off, with regression analysis to 
estimate a value for each of the health states.28 Valuation 
sets have since been obtained through various approaches 
in many other countries, and differences between valuation 
sets are generally small.29 The original EQ-5D scale using 
the UK valuations extends from –0.59 to 1.00,28 and a more 
recent UK value set for the EQ-5D-5L extends from –0.28 
to 0.95.30 The mean minimally important difference reported 
in a review of eight studies in different conditions was 0.074 
(range –0.011 to –0.140).31 A visual analog scale (VAS) is 
recommended for use alongside the EQ-5D. This consists of a 
“thermometer” scale from 0 to 100, on which the respondent 
is asked to indicate the point that best represents their own 
health on that day.
The Short Form (SF-6D) includes eleven items in six 
domains, including physical functioning, role limitations, 
social functioning, pain, vitality, and mental health.32 This 
instrument yields 18,000 health states. Items were extracted 
from the larger, 36-item instrument (SF-36), which was 
developed for the Medical Outcomes Study.33,34 Preference 
weights are obtained from a UK population-representative 
sample and models derived to provide utility values for each 
health state. The SF-6D scale extends from 0.29 to 1.00, and 
a review of eight studies in different conditions estimates 
the mean minimally important difference to be 0.041 (range 
from 0.011 to 0.097).31 The SF-36, and a shorter version – 
the SF-12 – are also still frequently used in studies to assess 
aspects of QoL more fully, where obtaining a utility value is 
not the primary objective.
The Health Utilities Index was developed in the early 
1980s in Canada to assess outcomes in low birth weight 
infants.35 Six domains are captured by HUI version 2 (HUI-2) 
including sensation, mobility, emotion, cognition, self-care, 
pain, and fertility.36 Each has between 3 and 5 levels, resulting 
in 24,000 possible health states. Valuations were originally 
obtained from Canadian parents using standard gamble and 
a VAS. Version 3 (HUI-3) expands the sensation domain into 
vision, hearing, and speech and yields 972,000 health states.37 
Valuations are elicited from the general public in Canada and 
a utility function estimates for each of the domains, and for 
the overall instrument.
Up to three decades of experience with these instruments 
highlights that they yield differing utility values in head-to-
head comparisons. In seven health conditions, not including 
vision disorders, SF-6D is found to have a smaller range and 
lower variance in values than EQ-5D.38 Differences result in 
the estimation of different estimates of quality-adjusted sur-
vival for the same intervention and thus differing conclusions 
in relation to cost-effectiveness. As a result, some funding 
bodies are explicit about which instrument and valuation 
method they prefer. In England, the National Institute for 
Health and Clinical Excellence (NICE) prefers EQ-5D, but 
even among NICE Technology Appraisals, there is consider-
able variation in the methods used to select and incorporate 
utility values in economic models.39 Health state valuations 
obtained from the general public, rather than from patients 
or clinical experts, are also generally preferred.
The limitation of generic PROMs is that they may lack 
sensitivity for the impact of eye disease and its treatment. For 
example, a vision-related QoL instrument, the Vision Func-
tion (VF-14), identified significant benefit of cataract surgery 
at 3 months, but the SF-36 found no significant benefit.40 
While the very brief preference-based generic QoL instru-
ments such as EQ-5D are unable to capture QoL outcomes 
comprehensively, their shortness and ease of administration 
face to face, or by telephone, postal questionnaire, SMS mes-
saging, web or email usually results in higher response, and 
completion rates than longer questionnaires. Moreover, the 
ability to transform raw scores into utility values provides 
wide application across different populations and medical 
specialties, thereby securing their role as important PROMs in 
informing resource allocation and reimbursement decisions, 
which typically have to make comparisons across a wide 
range of different disease areas. Partly in consequence, they 
are also increasingly used in medical product development.41
Some investigators, seeking instruments more sensitive 
to vision-related preference, have recommended use of the 
Vision Preference Value Scale, first validated in 2004, in 
which a score of 0 is equivalent to an outcome as bad as death, 
and a score of 1.0 is equivalent to perfect vision.42 However, 
caution is needed in interpreting the findings of studies using 
a “vision-truncated scale,” and scales anchored by vision are 
not generally used in cost-effectiveness analysis.43
vision-related PROMs
There are many instruments that focus on the impact of vision 
impairment and ocular symptoms and signs on different 
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domains of QoL, such as the NEI-VFQ-25, the IVI, and 
the VF-14. These are typically referred to as vision-related 
or ophthalmic PROM instruments, and for consistency we 
have used the former throughout. Khadka et al conducted 
a systematic review for vision-related PROM instruments 
demonstrating interval measurement properties and identi-
fied 48 (out of 121 instruments in total). They appraised the 
quality of each against criteria similar to those proposed 
by the “Consensus-based Standards for the selection of 
Measurement Instruments” group44 and highlighted those 
of higher quality, by ophthalmic subspecialty.45 Where no 
disease-specific PROM exists, the IVI has been proposed 
as being valuable for assessing domains including the abil-
ity to read and access information, mobility, and emotional 
well-being.17 A shorter version, the (15-item) Brief IVI, has 
also been validated.46
Impact of PROMs by ophthalmic 
subspecialty
It is beyond the scope of this review to critique all vision-
specific and eye disease-specific PROMs. The following 
sections highlight examples of the more frequently used, or 
better validated PROMs in ophthalmology, by subspecialty 
area, and illustrate examples of their impact.
Narrative review search methodology
We performed a PubMed search for “patient reported out-
come” and terms relating to each subspecialty, dated January 
1990 to September 30, 2018 with no field restrictions. This 
identified 4,114 hits (Table S1). We screened these to identify 
systematic reviews of PROMs, RCTs reporting PROMs, and 
examples of the use of PROMs in clinical practice. In addi-
tion, we reviewed the Cochrane Eyes and Vision database 
(https://eyes.cochrane.org/). This revealed that across all sub-
specialties, relatively few RCTs contained within systematic 
reviews of interventions have, to date, reported PROMs or 
economic outcome measures. Greatest progress in terms of 
developing PROMs and introducing them into RCTs have 
been made in low vision, medical retina and glaucoma.
Glaucoma
Vandenbroeck et al published a systematic review of PROM 
instruments in glaucoma in which the search, dated to 
December 2010, identified 27 instruments, 18 of which 
were disease specific.47 The authors highlighted that the 
instruments mostly lacked a conceptual framework, had 
been tested using classical validation techniques, and that 
item generation strategies had not involved the patients’ 
perspective adequately. Another systematic review by Che 
Hamzah et al, in which the search dated to January 2009, cat-
aloged 33 instruments.48 They highlighted the NEI-VFQ-25, 
IVI, and Treatment Satisfaction Survey-Intraocular Pressure 
(TSS-IOP) as having the highest content validity. Another 
review of PROM instruments by Khadka et al against qual-
ity criteria recommended the Modified Glaucoma Quality 
of Life questionnaire (GAL-9/10), as a higher quality 
instrument for assessing activity limitation and mobility.17 
These authors subsequently took a systematic approach to 
identify 737 unique content items for a Glaucoma-specific 
item bank and refined these into a minimally representative 
set containing 342 unique items in ten QoL domains.49 The 
authors highlighted that the majority of items were identified 
de novo from patient focus groups, rather than existing PRO 
instruments in glaucoma.
A review of trials and clinical studies registered with 
Clinicaltrials.gov, assessing the efficacy of minimally invasive 
glaucoma surgical devices, identified that only one of 51 
studies included health-related QoL as a secondary outcome 
measure.50 The recently published RCT protocol for the Treat-
ment of Advanced Glaucoma Study claims to be the first RCT 
to set patient perspectives as the primary outcome measure.51 
Table 1 summarizes RCTs in glaucoma that have included 
PROMs as primary outcome measures. This table highlights 
that the impact of PROMs has been relatively limited to date, 
with focus on anxiety levels between different treatments, but 
that RCTs are currently underway using PROMs as the key 
determinant of comparative efficacy.
Medical retina, uveitis, and vitreoretinal 
disease
A systematic review of retinal disease PROMs by Prem Sent-
hil et al (search date not specified) identified 217 studies, most 
frequently on AMD (108 studies), diabetic retinopathy (DR) 
(31 studies), and hereditary retinal dystrophies (29 studies). 
In total, 110 different PROM instruments were reported, more 
than half of which were generic (62 studies, most frequently 
the SF-36, and the Hospital Anxiety and Depression Scale 
[HADS]), followed by disease-specific (29 studies) and 
vision-related (19 studies, most frequently the NEI-VFQ 
and VF-14) instruments.24 Only three instruments had been 
rescaled and tested using Rasch analysis. They also critically 
appraised the psychometric performance of the instruments 
against criteria and identified numerous limitations. The 
authors reported that most instruments had limited content 
coverage, typically measuring only one or a few domains of 
QoL. In another study by Prem Senthil et al, semi-structured, 
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Table 1 impact of PROMs in glaucoma RCTs, highlighting only trials in which PROMs were selected as primary outcome measures
Study name N Intervention PRO outcome 
measures
Impact Reference
Tube versus 
Trabeculectomy Study
202 patients 
with previous 
trabeculectomy and/or 
cataract surgery
Tube shunt (350 mm2 
Baerveldt implant) vs 
trabeculectomy with 
MMC
Nei-vFQ composite 
score and minimally 
important difference
No significant 
difference at baseline 
or annual review for 
5 years
Kotecha et al110
Glaucoma Australia 
educational impact
101 newly diagnosed 
glaucoma patients
Glaucoma education vs 
control
Auckland Glaucoma 
Knowledge 
Questionnaire
Significant reduction in 
anxiety in intervention 
group
Skalicky et al111
Glaucoma intensive 
Treatment Study
242 glaucoma patients Topical drug 
monotherapy vs 
topical triple therapy 
plus 360 degree laser 
trabeculoplasty
eye-tem Bank 
Glaucoma module
Study Protocol 
Published
Lamoureux et al7
Bengtsson et al112
Treatment of 
Advanced Glaucoma 
Study
440 patients presenting 
with advanced open 
angle glaucoma
Medical therapy 
vs augmented 
trabeculectomy
Nei-vFQ at 24 m. 
eQ-5D-5L, HUi-3 and 
Glaucoma Utility index
Study protocol 
published
King et al51
Shared Care for 
Stable Glaucoma 
Patients
233 patients with stable 
glaucoma
Primary eye care vs 
specialist outpatient 
clinic
Patient satisfaction, 
cost
Comparable patient 
satisfaction, clinical care 
and management, but 
lower cost with PeC
Goh et al113
Laser in Glaucoma 
and OHT Trial
718 patients with 
glaucoma or OHT
Selective laser 
trabeculoplasty vs 
topical treatment
eQ-5D-5L, Glaucoma 
Utility index, GSS, 
Glaucoma QoL
Study protocol Gazzard et al8
Abbreviations: eDSQ, eye Drop Satisfaction Questionnaire; GSS, Glaucoma Symptom Scale; HADS, Hospital Anxiety and Depression Scale; OHT, ocular hypertension; 
QoL, quality of life; MMC, mitomycin C; PRO, patient-related outcome; Nei-vFQ, National eye institute-vision Function Questionnaire ; RCT, randomized controlled clinical 
trial; GiTS, Glaucoma intensive Treatment Study.
qualitative interview data from 79 patients with hereditary 
and acquired retinal diseases identified nine QoL domains 
relevant to both the groups, which were each explored and 
reported in detail. This paper provides a scientific basis for 
splitting vs lumping less common retinal diseases to develop 
a retina-specific PROM.52 Further work has formed the basis 
for a hereditary retinal disease item bank.53
A systematic review of clinical trial registries to identify 
uveitis trials reported that none out of 104 registered by 
October 2013 used a PROM as a primary outcome mea-
sure.54 The Core Outcome Set for Uveitic Macular Oedema 
(COSUMO) study aims to develop a core outcome set for 
trials, using systematic review, qualitative research with 
focus groups, and a Delphi process to reach consensus.55 A 
core outcome set is also being developed by the Outcome 
Measures in Rheumatology (OMERACT) Vasculitis Work-
ing Group for Behcet’s disease, which includes the ocular 
manifestations.56 Another core outcome set has been pro-
posed for JIA-associated uveitis.57 The Multicenter Uveitis 
Steroid Treatment study (MUST) investigators reported that 
their trial, comparing systemic or implanted corticosteroid 
therapy in 255 patients, was underpowered to explore sec-
ondary outcomes of interest including QoL, highlighting the 
importance of considering sample size in future comparative 
effectiveness trials.58 Table 2 provides examples of the inclu-
sion of PROMs in uveitis RCTs. The examples illustrate that 
PROMs are making an important impact in this specialty, 
where identification of traditional outcome metrics (eg, cells 
in the vitreous) that correlate meaningfully with the patient-
centered experience of disease and its treatment has been 
more challenging likely due to the reliance on non-disease-
specific instruments.
Krezel et al systematically reviewed the frequency and 
type of PROMs used in RCTs for AMD published between 
2010 and 2013.59 They reported 177 RCTs including 858 
outcomes, of which 38 outcomes were PROMs (4.4%), and 
these were included in 25 trials (14.1%). The NEI-VFQ 
was the most frequently used instrument. A minimum set of 
standardized outcome measures has been defined for macular 
degeneration and promoted internationally, recommend-
ing IVI be used due to its three measurable traits and valid 
interval scaling.60 However, there are currently no PROMs 
that are clinically validated and acceptable to regulatory 
agencies for drug development in intermediate AMD, and 
development of another novel PROM has been proposed.61 
In a study reviewing health state utility values in AMD and 
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their use in health care decision-making, Butt et al highlight 
that generic health-related QoL instruments may lack sen-
sitivity in AMD and that the choice of a utility value should 
be explicitly critiqued given the existing variability in utility 
values derived by different studies.62
PROMs have been used to assess diabetic eye disease 
for many years. In the landmark Diabetes Control and 
Complications Trial/Epidemiology of Diabetes Interven-
tions and Complications, intensive diabetes therapy in this 
cohort modestly improved NEI-VFQ score at 30 years.63 
However, reviews in the past decade have highlighted the 
importance of capturing the patient perspective in diabetic 
retinopathy more comprehensively,64 including the need to 
measure its social and emotional impact through further 
PROMs development.65 A systematic and comprehensive 
approach to identify the content for inclusion in a DR 
item bank yield 1,165 unique items that were winnowed 
to a minimally representative set of 314 items across nine 
domains of QoL.66,67 Initial evaluation of DR and DME 
item banks has been undertaken using computer adaptive 
testing (CAT).68
Table 3 provides examples of landmark RCTs in medi-
cal retina in which PROMs have had an impact. Many of 
these trials have used PROMs not only to demonstrate 
improvement in patient experience in comparison with 
sham interventions, but also, importantly, to demonstrate 
non-inferiority of QoL outcomes for interventions differing 
dramatically in cost. Such trial data have very important 
health policy implications. A very recent example is the 
NICE guideline (2018) to recommend the more cost-effec-
tive anti-VEGF therapy bevacizumab as an effective therapy 
for the treatment of AMD in the UK’s NHS. PROM data 
(mostly using the NEI-VFQ-25 and SF-36) contributed to 
this policy decision.69 No vitreoretinal PROMs were identi-
fied by our search.
Cataract
The first vision-related activity limitation instrument for 
cataract was introduced in 1992, and a review of question-
naires published since 1992 explored the relative merits and 
psychometric properties of each.18 Another review compared 
16 Rasch-scaled cataract questionnaires before, and 6 months 
after, cataract surgery.70 This study found the Catquest-9SF 
to be the most responsive to cataract surgery and, being 
short, was advocated as the best tool for measuring visual 
functioning outcomes in trials and routine practice. A mini-
mum standardized outcome set has been proposed interna-
tionally for cataract surgery, which includes administration 
of Catquest-9SF pre- and 3-months postoperatively.71 This 
instrument has also been included as a secondary outcome 
measure in a recent RCT protocol (The FACT trial).72 A 
newer PROM, Cat-PROM5, has been tested head-to-head 
against Catquest-9SF in 822 typical NHS cataract surgery 
patients and, as an even shorter instrument, advocated as 
Table 2 impact of PROMs in uveitis RCTs, illustrating inclusion of PROMs as secondary outcome measures (no RCTs found including 
PROMs as primary outcome measure)
Study name N Intervention Outcome 
measures
Impact Reference
viSUAL-1 and 
viSUAL-2
217 with active (viSUAL 
1), 226 with inactive 
(viSUAL-2) uveitis
Subcutaneous 
adalimumab vs placebo
Nei vFQ-25 
composite 
score
Significant improvement in QoL in 
both trials in the treatment group 
comparing baseline to final visit
Sheppard et al114
SAKURA 347 posterior 
noninfectious uveitis
intravitreal sirolimus, 
3 doses
Nei-vFQ-25 The composite score and mental 
health subscore are relevant visual 
function response measures
Lescrauwaet 
et al115
RCT on 
antimetabolites for 
noninfectious uveitis
80 with noninfectious 
intermediate, posterior, 
or panuveitis
Oral methotrexate 
25 mg weekly or oral 
mycophenolate mofetil 
1 g bd
indian vFQ and 
SF-36 at 6 m
Both the treatments improved 
vision-related QoL (but not 
health-related) compared to 
baseline, but both also worsened 
mental health
Niemeyer et al116
HURON 244 with noninfectious 
intermediate or 
posterior uveitis
Ozurdex implant vs 
sham
Nei-vFQ, 
SF-36, SF-6D, 
euroQol-5D
Significant differences were 
identified for uveitis participants 
vs general population, except with 
SF-36 physical component and 
eQ-5D
Naik et al117
Abbreviations: Nei-vFQ, National eye institute visual Function Questionnaire, QoL, quality of life; RCT, randomized controlled clinical trial; SF, Short Form; vFQ, vision 
Function Questionnaire; PROM, patient-reported outcome measures.
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Table 3 impact of PROMs in medical retina RCTs, highlighting two RCTs in which the PROM was the primary outcome measure
Study name N Intervention Outcome measures Impact Reference
MARiNA and 
ANCHOR
646 (MARiNA) and 
379 (ANCHOR) 
patients with wet 
AMD
Ranibizumab vs sham 
or photodynamic 
therapy
Nei-vFQ-25 at 
baseline, 12 and 24 
months
improvement in outcomes with 
intervention
Bressler et al118
SCORe2 Report 5 362 with CRvO or 
HRvO and macular 
edema
intravitreal 
bevacizumab vs 
aflibercept
Nei-vFQ-25 
composite and 
subscale scores
Non-inferiority of bevacizumab Scott et al119
OZDRY 100 patients with 
refractory center 
involving DMe
5-monthly fixed dosing 
vs OCT-guided pro-
re-nata regimen of 
Ozurdex
Retinopathy-
Dependent QOL, Nei 
vFQ-25, (RetTSQ) 
(primary outcome)
No significant difference at 
month 12
Ramu et al120
ivAN 610 with active wet 
AMD
Ranibizumab vs 
bevacizumab, 
continuous or 
discontinuous
eQ-5D Similar efficacy of drugs in terms 
of visual acuity. Continuous 
ranibizumab cost £3.5 million 
per QALY compared with 
bevacizumab
Chakravarthy 
et al121
RiDe and RiSe 382 RiDe and 377 
RiSe patients with 
center-involving  
DMe
Ranibizumab vs sham Nei-vFQ 25 at 
baseline, 12, and 24 
months
Treatment improved vision-
related function significantly 
more than sham
Bressler et al122
ReSTORe Open-
label extension
303 with DMe Ranibizumab 0.5 mg vs 
laser monotherapy
Nei-vFQ-25 (primary 
outcome)
Greater gain in ranibizumab 
group at 12 months, with similar 
gain in both the groups treated 
with open-label extension from 
12 to 24 months
Mitchell et al123
BevORDeX 61 patients with 
center-involving  
DMe
Ozurdex implant 
every 16 weeks vs 
bevacizumab every 4 
weeks
ivi Both the groups had significant 
improvement in ivi scores
Gillies et al124
MACUGeN 260 with center-
involving DMe
Pegaptanib sodium vs 
sham, with focal/grid 
laser
Nei-vFQ-25, eQ-5D Clinically and statistically 
significant differences between 
groups in composite and sub-
scores, no difference in mean 
change in eQ-5D utility scores
Loftus et al125
BRAvO and 
CRUiSe
397 with branch and 
392 with central 
retinal vein occlusion 
and macular edema
Ranibizumab vs sham Nei-vFQ-25 Treatment results in significant 
mean improvement in 
composite score compared to 
sham from month 1
varma et al126
Abbreviations: AMD, age-related macular degeneration; BRvO, branch retinal vein occlusion; CRvO, central retinal vein occlusion; DMe, diabetic macular edema; ivi, 
impact of vision impairment; Nei-vFQ, National eye institute visual Function Questionnaire; RetTSQ, Retinopathy Treatment Satisfaction Questionnaire; PROM, patient-
reported outcome measures; RCT, randomized controlled clinical trial.
being preferred by patients, and better suited for use in high 
volume routine surgical practice.73
Amblyopia, strabismus, and pediatric 
ophthalmology
Kumaran et al conducted a systematic review of PROMs in 
amblyopia and strabismus published up to July 2016.74 This 
identified 71 PROMs of which 32 were amblyopia and/or 
strabismus specific, but only four of these had been subjected 
to psychometric tests, and only the adult strabismus ques-
tionnaire (AS-20) demonstrated good measurement proper-
ties. The authors concluded that all instruments had gaps in 
their content and failed to assess QoL comprehensively and 
proposed the development of an item bank to address this. 
Another review recommended the Modified AS-20 instru-
ment, which measures self-perception, interaction, reading, 
and general function, as one of the strongest of the existing 
instruments.17,75 Incorporation of AS-20 QoL question-
naires into pre- and postoperative clinical practice has been 
proposed, on account of finding that many  apparent surgical 
failures report subjective improvement.76
Tadić et al conducted a systematic review of PROMs for 
ophthalmic disorders in children, and identified 17 instru-
ments, of which 11 were condition-specific and six were 
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for children and young people with visual impairment. The 
authors recommended the need for the development of new 
instruments.77 Tadić and Rahi further elaborated on issues 
particular to the development of PROMs for use in children.78 
These include conflation between theoretically distinct 
vision-related constructs and outcomes, the importance of 
developmentally appropriate approaches to design and appli-
cation, the feasibility of administering self-report standard 
questionnaire formats to visually impaired children, ethical 
issues, and statistical issues. More recently, Hatt et al have 
identified a comprehensive list of child- and parent-derived 
items from 180 children and 328 parents, which they grouped 
into 614 unique items identified by children in 36 subgroups, 
and 589 items identified by parents in 61 bins. The authors 
report that they intend to develop a formal set of pediatric 
PROMs from this pool.79
Cornea and external disease
A systematic review of PROMs for surgically amenable 
epiphora identified that 69% of 227 studies included a 
PROM as the primary outcome measure, although in 48% 
the PROM was a single-item symptom score.80 The authors 
critically appraised each PROM and concluded that they 
lacked adequate content validity. In Primary Sjogren’s 
Syndrome, qualitative work and PROM development have 
been done to identify 484 items covering 86 concepts in 3 
dimensions impacting QoL.81,82 In the TEARS trial (Toler-
ability and Efficacy of Rituximab in Primary Sjogren’s Syn-
drome), SF-36 scores were found to be strongly associated 
with patient-reported symptoms.83 A review of PROMS for 
use in RCTs of dry eye identified 18 instruments, some of 
which were generic, many of which focused on symptoms, 
and concluded that very few available PROMs satisfy FDA 
guidance on the requirements of a suitable PROM to be 
acceptable as support for a label claim in support of a drug 
or medical device.84 The first RCT (n=16) to demonstrate the 
beneficial effects of autologous serum in patients with severe 
ocular surface disease used a daily subjective symptom scale, 
the Rasch-scored Faces scale, to demonstrate a significant 
effect of the intervention.85
While limited PROMs have been designed for use in 
corneal diseases, Catquest-9SF has been validated for use in 
patients who have had corneal transplant surgery.86
Refractive error
Kandel et al conducted a systematic review for studies 
using PROMs to assess refractive surgery outcomes.87 
They identified 27 instruments, 12 of which were specific 
to refractive error. The authors reported that while the NEI 
Refractive Error Quality of Life instrument (NEI-RQL) was 
the most frequently used, it did not provide valid measure-
ment, whereas a number of other instruments, including the 
Quality of Vision, Near Activity Visual Questionnaire, and 
Quality of Life questionnaire (QIRC) had been constructed 
using Rasch analysis and were suited to measurement of 
visual symptoms, activity limitations, and QoL, respectively. 
They subsequently developed a pool of refractive error items 
from patient groups in Australia (n=337 items) and Nepal 
(n=308 items), spanning 12 QoL domains and are working 
to develop a CAT system suitable for use in both high- and 
low-income country settings.88 An RCT using PROMs as the 
primary outcome measure to compare ready-made spectacles 
and custom-made spectacles for the correction of refractive 
error in adults in India found that both result in comparable 
patient satisfaction and large gains in visual function and 
QoL, with the custom-made spectacles achieving a small but 
statistically significant higher QoL outcome.89
Oculoplastics
A systematic review of PROMs for eyelid, orbit, and lacrimal 
disorders, conducted in 2013, identified ten generic and 32 dis-
ease-specific instruments and assessed their content domains 
and psychometric quality.90 The SF-36 and NEI-VFQ-25 were 
the most frequently used generic instruments, and thyroid eye 
disease was the most studied condition. Of the 32 disease-
specific instruments, 13 were developed for eyelid-related 
disease, ten for orbital disease, and nine for lacrimal disease. 
Physical function and self-image were the most frequently 
studied domains of QoL. The authors reported that the majority 
of instruments had very limited psychometric development and 
poorly defined content domains and concluded that efforts to 
develop PROMs in oculofacial surgery had been sparse, frag-
mented, and generally rudimentary, making assimilation into 
daily clinical practice challenging. More recently, the FACE-Q 
Eye Module has been developed for use in cosmetic eye treat-
ments and contains four scales measuring appearance of the 
eyes, upper and lower eyelids and eyelashes,91 and a module 
for children and young adults with diverse conditions causing 
facial appearance differences has also been developed.92 While 
there have been a few further clinical studies reported since 
2013, no RCTs utilizing PROMs as key outcome measures 
were identified by our search.
Neuro-ophthalmology
We identified one systematic review of PROMs for use 
in patients with vision impairment following stroke, 
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which identified 34 vision-specific PROMs, and critically 
appraised the quality of the identified instruments.93 The 
authors highlighted four high-quality instruments, includ-
ing NEI-VFQ, Activity Inventory (AI), Daily Living Tasks 
Dependent on Vision (DLTV), and the Veterans Affairs Low 
Visual Function Questionnaire (VA LV VFQ), but cautioned 
that these had each only been assessed in a limited number 
of patients.
There were no other systematic reviews of PROM instru-
ments for neuro-ophthalmic conditions, and only scattered 
examples of PROMs that have been developed for specific 
conditions. A neuro-ophthalmic module was developed for 
the NEI-VFQ.94 This was assessed for content and quality 
by Ramey et al and considered to perform reasonably well 
by classical test criteria.90 Generic instruments including 
NEI-VFQ and SF-36 have been used in an RCT in idiopathic 
intracranial hypertension (IIH) patients,95 and in a study 
of neurofibromatosis (NF) type 2.96 The Children’s Visual 
Function Questionnaire has been proposed as a secondary 
endpoint for clinical trials in children with NF1-associated 
optic pathway gliomas.76 Disease-specific instruments have 
been developed for patients with neuromyelitis optica spec-
trum disorders.97,98 The first use of a PROM information 
system utilizing CAT in patients with neurofibromatosis has 
also been reported.99
Low vision
A literature review of RCTs on low vision rehabilitation 
identified 15 trials, utilizing nine PROMs, and one hybrid 
PROM and performance-based outcome measure, the 
Melbourne Low-Vision ADL Index.100 The other instru-
ments included the AI, Canadian Occupational Performance 
Measure, Functional Assessment Questionnaire, Groningen 
Activity Restriction Scale, IVI, Katz’ Index of Activities 
of Daily Living, Low Vision QOL, NEI-VFQ, and the VA 
LV VFQ. Most of these instruments (seven out of ten) have 
utilized Rasch or IRT modeling, have been validated for use 
in low-vision populations, and include items in a number of 
different domains. The Veterans Affairs Low Vision Interven-
tion Trials (LOVIT I and II) used LV VFQ-48 as the primary 
outcome measure. Significant benefit on reading ability at 
4 months was demonstrated for low-vision rehabilitation 
(n=126 patients with low vision from macular disease).9 The 
LOVIT II trial randomized 323 patients to receive low vision 
devices with or without rehabilitation therapy and found that 
the latter group improved more in all visual function domains 
except mobility.10
The Impact of PROMs in routine 
clinical practice
Our search identified very few examples of the use of PROMs 
in routine clinical practice. Clinicians may be more likely 
to report such progress and real-life experience in the gray 
literature and unpublished sources, and we recognize that this 
is a limitation of this narrative, rather than systematic, review 
of the published literature indexed in PubMed.
The Swedish National Cataract Outcome Study (1995–
1999) prospectively administered Catquest-9SF, before and 
after surgery, to 8,595 patient eyes and demonstrated greater 
impact on satisfaction, and surgical benefit to vision, of 
second-eye surgery.101 A similar finding was reported when 
Catquest-9SF was administered to 870 patients in five Dutch 
hospitals.102 Data for the Swedish National Outcome Study 
(2008–2011), on 9,707 patient eyes before and after surgery, 
further revealed large variation in PROMs, influenced by 
factors including the degree of anisometropia, indication 
for surgery, and postoperative problems.103 These examples 
highlight the value of implementing PROMs in real-world 
clinical practice and Illustrate that they may reveal patient 
preferences unexpected by clinicians and policy makers.
Hee et al recently explored the feasibility of implementing 
glaucoma PROMs in daily clinical practice in Singapore.104 
They reported that while the majority of health care profes-
sionals and patients felt that the four glaucoma PROMs 
selected for use in this study were relevant to them, there 
were multiple barriers to their routine use. These included 
the need for brevity, yet the desire for a more comprehensive 
instrument able to capture patient concerns more fully, and 
the challenge for patients with vision impairment to self-
administer the instrument on paper. Furthermore, respond-
ers highlighted the desire for inclusion of measurement of 
financial impact. The authors highlighted that participation 
in completing PROMs was much lower among patients from 
lower socioeconomic and education backgrounds, who tend 
to be those most severely affected by eye disease.
A single PROM for all ophthalmic 
situations?
The previous section outlines considerable achievements 
in recent years to develop PROMs for the most prevalent 
eye diseases globally. In some ophthalmic subspecialties, 
such as low vision, medical retina, and glaucoma, PROMs 
are frequently included as secondary, and increasingly as 
primary, outcome measures in clinical trials, and are being 
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explored for integration into routine clinical practice. Other 
subspecialties are still at an earlier stage of developing and 
assessing PROMs that target the impact of the key diseases 
and treatments. There is a dearth of PROMs for rarer diseases, 
especially in neuro-ophthalmology. The issues particular 
to PROM research in rare diseases have been explored by 
Slade et al.105 A key challenge is the time it takes to develop a 
valid and reliable PROM. High-quality PROM development 
requires extensive qualitative work with patients and focus 
groups, pilot studies in which a long set of potential items 
are administered to patients, psychometric data analysis and 
winnowing of redundant items, before validation of the final 
instrument in clinical practice and trials, and PROMs are not 
necessarily directly applicable in differing cultural contexts.
One solution is to develop a very large bank of items 
and to validate subsets of questions from this bank in many 
different diseases and patient populations.106 Methods to 
develop one such “Eye-tem bank” to measure vision and 
eye disease-related QoL have been outlined.17 This bank is 
being developed across 13 disease groups, namely AMD, 
cataract, glaucoma, DR, retinal detachment, other vitreo-
retinal, cornea, refractive error, uveitis, other inflammation, 
amblyopia and strabismus, lacrimal and ocular surface, and 
neuro-ophthalmology.17 While CAT can be used to target 
items to the dynamic responses of each individual responder, 
further work will be needed to ascertain the time response 
burden and acceptability of such comprehensive tools in both 
research and clinical practice settings.
Another approach is to routinely include at least one 
generic PROM such as the EQ-5D alongside the wide range 
of vision and eye disease-related PROMs currently being 
used.
Future research priorities
Guidelines for the inclusion of patient-reported outcomes 
in clinical trial protocols and reporting guidelines have 
been developed: the SPIRIT-PRO and CONSORT-PRO 
Extensions, respectively.107 Standardization of vision-related 
PROMs is needed, and progress toward achieving this has 
been made in other fields. For example, the SISAQOL con-
sortium, “Setting International Standards in analyzing PRO 
and QOL endpoints for cancer clinical trials,” is developing 
standardized approaches for the analysis of PROM data in 
cancer.108
A systematic review has identified methodological 
frameworks to measure the health care impact of research.109 
Beyond measuring PROMs more precisely, reliably, and 
comprehensively in the future, further research is needed to 
better understand and demonstrate the impact of measuring 
PROMs in ophthalmic research and clinical practice.
Conclusion
There is much improved awareness of PROMs among both 
researchers and clinicians over recent decades, but much 
work needs to be done to standardize the outcomes and the 
measures. PROMs provide a unique and exciting opportunity 
to capture what matters to patients and to inform understand-
ing of all stakeholders. Through influencing the decisions 
of clinicians, regulators, and policy makers involved in the 
care of patients with ophthalmic diseases, PROMs have the 
potential to transform medical care.
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Table S1 PubMed search
Search Keywords in search PubMed hits
1 Patient reported outcome 79,103
2 1 AND glaucoma 190
3 1 AND cataract 394
4 1 AND (cranial nerve palsy OR diplopia OR myasthenia OR intracranial hypertension OR neuro-ophthalmology 
OR optic nerve OR optic neurotos OR optic disc OR extraocular)
1,131
5 1 AND (retinopathy) OR macular degeneration) OR macular dystrophy) OR retinal dystrophy) OR retinal 
degeneration) OR maculopathy) OR retina) OR macula)) OR retinitis) OR uveitis) OR choroiditis) OR 
chorioretinitis
653
6 1 AND strabismus) OR amblyopia) OR squint) OR ocular motility) OR pediatric ophthalmology)) 183
7 1 AND adnexal) OR oculoplastic) OR lid) OR eyelid) OR orbit 514
8 1 AND vitreous) OR vitreoretina*) OR epiretina*) OR vitreomacula* 150
9 1 and Cornea or refractive 364
10 1 and low vision or vision impaired or visually impaired 535
Total screened 4,114
